30/05/2015 - 15:44
CHICAGO – Immune checkpoint inhibition with nivolumab every 2 weeks provides a better response than does standard treatment for advanced liver cancer, phase I/II results suggest.
The overall...
Field of Interest: Oncology
Categories:
News Feed: Internal Medicine News - Oncology